Xencor Picks 400 mcg/kg XmAb819 Dose, Targets Phase 3 by End-2027
XNCR has more than doubled off its 52-week low of $10.375.
Summary
Xencor reported updated Phase 1 data for XmAb819 in advanced ccRCC, selected 400 mcg/kg as the proposed Phase 3 dose on a 45.5% confirmed ORR, and said cash now funds operations into 2029.
Key Events · Product Development and Regulatory · XNCR
-
XmAb819 Phase 1 Data Updated
At the 400 mcg/kg dose, 5 of 11 efficacy-evaluable patients had confirmed partial responses (45.5% cORR), with one additional unconfirmed response (55% uORR).
-
400 mcg/kg Selected as Phase 3 Dose
Citing the 45.5% cORR, an 82% six-month PFS estimate, and safety consistent with lower dose cohorts, Xencor chose 400 mcg/kg IV as the proposed recommended Phase 3 dose.
-
Cash Runway Extended Into 2029
Item 2.02 states the company expects cash to fund research and development programs and operations into 2029.
-
Phase 3 Design and FDA Path
A global randomized trial vs tivozanib is planned, with an end-of-Phase 1 meeting in 1H2027 to discuss a potential accelerated approval pathway; a registration-enabling study is targeted by year-end 2027.
Analysis · XNCR · Life Sciences
The numbers in Xencor's 8-K, which furnishes the ESMO presentation and press release with updated Phase 1 data for XmAb819 in advanced ccRCC, support moving the program forward: 45.5% confirmed ORR at the 400 mcg/kg dose, 55% unconfirmed ORR, and an 82% six-month PFS estimate. Xencor selected 400 mcg/kg as the proposed IV Phase 3 dose and plans a global randomized trial against tivozanib, with an end-of-Phase 1 meeting with FDA in 1H2027 to discuss a potential accelerated approval path. Cash runway into 2029, also stated in the filing, removes near-term financing risk. The main risk is that the 400 mcg/kg cohort is small (11 efficacy-evaluable patients) and the data are early; the full 20+ patient set is expected in 1H2027.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XNCR was trading at $34.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $10.38 to $30.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.